5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase inhibitors (TKIs). After progression, the choice of treatment is between chemotherapy and immune checkpoint inhibitors, but the role of EGFR mutation in the response to immunotherapy is still unclear. A network meta-analysis was performed and 4 randomized trials comparing immune checkpoint inhibitors versus chemotherapy were identified. A Bayesian network meta-analysis was carried out to compare three checkpoint inhibitors (nivolumab, pembrolizumab and atezolizumab) versus chemotherapy (docetaxel), evaluating their Hazard Ratio (HR) and 95% Confidence Interval (CI) for Overall Survival (OS). Results suggest that patients with NSCLC and EGFR mutation, previously treated with TKIs, show better OS when treated with docetaxel in comparison to checkpoint inhibitors treatment.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

          We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Approaches to interpreting and choosing the best treatments in network meta-analyses

            When randomized trials have addressed multiple interventions for the same health problem, network meta-analyses (NMAs) permit researchers to statistically pool data from individual studies including evidence from both direct and indirect comparisons. Grasping the significance of the results of NMAs may be very challenging. Authors may present the findings from such analyses in several numerical and graphical ways. In this paper, we discuss ranking strategies and visual depictions of rank, including the surface under the cumulative ranking (SUCRA) curve method. We present ranking approaches’ merits and limitations and provide an example of how to apply the results of a NMA to clinical practice.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

                Bookmark

                Author and article information

                Journal
                Oncotarget
                Oncotarget
                Oncotarget
                ImpactJ
                Oncotarget
                Impact Journals LLC
                1949-2553
                4 January 2019
                4 January 2019
                : 10
                : 2
                : 209-215
                Affiliations
                1 Oncology and Hematology Department, Oncology Unit, Piacenza General Hospital, Piacenza, Italy
                Author notes
                Correspondence to: Luigi Cavanna, l.cavanna@ 123456ausl.pc.it
                Article
                26541
                10.18632/oncotarget.26541
                6349440
                894fd05f-25b1-4d18-8882-f8afa69a294e
                Copyright: © 2019 Cavanna et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 8 November 2018
                : 10 December 2018
                Categories
                Meta-Analysis

                Oncology & Radiotherapy
                immuno-oncology,immunotherapy,nsclc,egfr mutation,chemotherapy
                Oncology & Radiotherapy
                immuno-oncology, immunotherapy, nsclc, egfr mutation, chemotherapy

                Comments

                Comment on this article